Illuminating Turner Syndrome

14 February 2020
rare_diseases_credit_depositphotos

February is Turner Syndrome Awareness Month, an opportunity to shine a light on this rare chromosomal disorder. Dr Nicola Davies outlines the physiology underlying Turner Syndrome (TS), current therapeutic options, and treatments on the horizon.

Two is better than one

Humans normally have 23 pairs of chromosomes, two of which define gender-specific traits; women have an XX pair and men an XY pair. However, approximately 1 in 2,000 females have either partial or complete absence of one X chromosome. This chromosomal anomaly is known as Turner Syndrome (TS) and was named after the endocrinologist Henry Turner who first described the condition in 1938.1

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight